Apparatus and method for prediction of rapid symptomatic blood pressure decrease

Patent metadata

Field	Value
Publication number	US-10980431-B2
Application number	US-201013519559-A
Country	US
Kind code	B2
Filing date	Dec 22, 2010
Priority date	Dec 28, 2009
Publication date	Apr 20, 2021
Grant date	Apr 20, 2021

Abstract

A monitoring device is included in a medical system to implement a method for prediction of a rapid symptomatic drop in a subject's blood pressure, e.g. during a medical treatment such as dialysis. To this aim, a pulse shape parameter (pPS) with respect to a pulse generator of the subject is registered by means of a pressure sensor arranged in an extracorporeal blood flow circuit coupled to a cardiovascular system of the subject (P). The pressure sensor is configured to detect pressure variations in blood vessels of the subject (P). It is investigated, during measurement period, whether or not one or more of the pulse shape parameters fulfil a decision criterion. An output signal (a) is generated if the decision criterion is found to be fulfilled, to indicate a predicted rapid symptomatic blood pressure decrease in the subject (P). The decision criterion may operate on pulse magnitude measures calculated for the received pulse shape parameters (pPS), or statistical dispersion measures calculated based on the thus-calculated pulse magnitude measures.

First claim

The invention claimed is:

1. A blood treatment device comprising:
an extracorporeal blood flow circuit configured to be coupled to a cardiovascular system of a subject;
at least one pressure sensor configured to generate measurement data based on pressure present within the extracorporeal blood flow circuit; and
a monitoring device for predicting rapid symptomatic blood pressure decrease during the subject's blood treatment, the monitoring device including:
an input for receiving the measurement data from the at least one pressure sensor in the extracorporeal blood flow circuit configured to be coupled to the cardiovascular system of the subject, the measurement data comprising a time sequence of pulse shape parameters representing pressure variations in at least one blood vessel of the subject; and
a data analysis part configured to repeatedly receive the pulse shape parameters, calculate a pulse measure representing an overall magnitude determined by averaging a plurality of magnitudes from a plurality of the pulse shape parameters within a time window, and cause an output signal to be generated when the pulse measure fulfils a decision criterion, the output signal indicating a predicted rapid symptomatic blood pressure decrease in the subject,

wherein, when the pulse measure fulfils the decision criterion, the output signal causes the blood treatment device to (i) issue an alarm indicating that a treatment parameter of the subject's blood treatment should be adjusted, and (ii) adjust the treatment parameter of the subject's blood treatment.

2. The blood treatment device of claim 1 , wherein the decision criterion includes when the pulse measure crosses a threshold.

3. The blood treatment device of claim 1 , wherein the decision criterion includes when the pulse measure remains outside of a threshold for a predefined test period.

4. The blood treatment device of claim 1 , wherein the data analysis part is further configured to:
obtain a reference measure;
calculate, during a measurement period, a respective pulse measure based on each of a number of the received pulse shape parameters;
investigate, during the measurement period, whether or not the decision criterion, which is given relative to the reference measure, is fulfilled based on one or more of the respective pulse measures; and
if so, cause the output signal to be generated.

5. The blood treatment device according to claim 4 , wherein the respective pulse measure is a pulse magnitude measure of a pulse shape parameter.

6. The blood treatment device according to claim 5 , wherein the pulse magnitude measure is any of a peak-to-peak measure, an integration measure, an energy measure, and a frequency spectrum intensity measure calculated for the pulse shape parameter.

7. The blood treatment device according to claim 4 , wherein the respective pulse measure is a statistical dispersion measure of a sequence of pulse magnitude measures.

8. The blood treatment device of claim 7 , wherein the data analysis part is further configured to:
investigate whether one or more of the pulse magnitude measures fulfils a second decision criterion relative to a second reference measure, and cause the output signal to be generated as a function of both said decision criterion and said second decision criterion.

9. The blood treatment device according to claim 7 , wherein the statistical dispersion measure is any of a variance, a standard deviation, a coefficient of a variation, a variance-to-mean, a sum of differences, and an energy measure.

10. The blood treatment device according to claim 4 , wherein the reference measure is a threshold value, and the decision criterion is fulfilled when the respective pulse measure passes the threshold value.

11. The blood treatment device according to claim 10 , wherein the threshold value is given by a predefined value.

12. The blood treatment device according to claim 4 , wherein the data analysis part further is configured to:
calculate as the reference measure an initial pulse measure based on at least one pulse shape parameter received at a first instance; and
store the initial pulse measure in a memory device associated with the monitoring device;
wherein the measurement period is subsequent to the first instance.

13. The blood treatment device according to claim 12 , wherein the data analysis part is configured to regard the decision criterion as fulfilled if:
an examined pulse measure fulfils a first partial decision criterion calculated based on the initial pulse measure; and
a predetermined amount of the respective pulse measures calculated within a subsequent test period fulfils a second partial decision criterion.

14. The blood treatment device according to claim 13 , wherein the predetermined amount is a value representing approximately 50% to approximately 100% of the respective pulse measures calculated for the pulse shape parameters received within the test period.

15. The blood treatment device according to claim 13 , wherein the predetermined amount represents all the respective pulse measures calculated for the pulse shape parameters received within the test period.

16. The blood treatment device according to claim 13 , wherein the test period is an interval selected from a range extending from approximately one minute to approximately fifteen minutes.

17. The blood treatment device according to claim 16 , wherein the test period is approximately five minutes long.

18. The blood treatment device according to claim 12 , wherein the data analysis part is configured to calculate the decision criterion by:
normalizing the initial pulse measure, and
dividing the normalized initial pulse measure by a predefined denominator.

19. The blood treatment device according to claim 18 , wherein
the data analysis part is configured to, during the measurement period, calculate the respective pulse measure for the received pulse shape parameter by dividing an original measure with the initial pulse measure.

20. The blood treatment device according to claim 18 , wherein the respective pulse measure is a pulse magnitude measure, and the predefined denominator is a value selected from a range extending from approximately 1.2 to approximately 5.

21. The blood treatment device according to claim 18 , wherein the respective pulse measure is a statistical dispersion measure, and the predefined denominator is a value selected from a range extending from approximately 0.2 to approximately 0.8.

22. The blood treatment device according to a claim 12 , which is configured to predict rapid symptomatic blood pressure decrease in the subject undergoing blood treatment, wherein the data analysis part is configured to calculate the initial pulse measure based on one or more pulse shape parameters received during an initial phase of the blood treatment.

23. The blood treatment device according to claim 1 , wherein the pulse measure relates to one or more physiological pulses in the pulse shape parameter, said one or more physiological pulses originating from a physiological pulse generator in the subject.

24. The blood treatment device according to claim 23 , wherein each pulse shape parameter corresponds to the time window in a pressure signal formed by the measurement data.

25. The blood treatment device according to claim 24 , wherein the time window is selected such that each pulse shape parameter comprises at least one physiologic

Assignees

• Olde Bo
• Solem Kristian
• Gambro Lundia Ab

Inventors

• Olde Bo
• Solem Kristian

Classifications

• A61B5/0215 Primary

  by means inserted into the body · CPC title

• A61M1/3639

  Blood pressure control, pressure transducers specially adapted therefor · CPC title